دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Double Standards and Inconsistencies in Access to Care—What Constitutes a Cosmetic Treatment?
John S. Barbieri, MD, MBA1,2; Avery LaChance, MD, MPH1; Joerg Albrecht, MD, PhD3,4
doi : 10.1001/jamadermatol.2022.6322
March 2023, Vol 159, No. 3, Pages 244-348
Therapeutic Relief for Erythrodermic Atopic Dermatitis
Dawn Z. Eichenfield, MD, PhD1,2
Differentiating Activity From Damage—The Morphological Challenge of Morphea
Amanda M. Saracino, MBBS, BMedSci, PhD1,2; Mandana Nikpour, MBBS, PhD3
Efficacy and Safety of Dupilumab in Patients With Erythrodermic Atopic DermatitisA Post Hoc Analysis of 6 Randomized Clinical Trials
Amy S. Paller, MD1,2; Jonathan I. Silverberg, MD, PhD3; Michael J. Cork, PhD4; Emma Guttman-Yassky, MD, PhD5,6; Benjamin Lockshin, MD7; Alan D. Irvine, MD8; Moon Bum Kim, MD9; Kenji Kabashima, PhD10; Zhen Chen, PhD, MS, MA11; Yufang Lu, MD, PhD11; Ashish Bansal, MD11; Ana B. Rossi, MD12; Arsalan Shabbir, MD11
doi : 10.1001/jamadermatol.2022.6192
Importance Erythrodermic atopic dermatitis (AD) is a severe AD subtype defined by extensive skin involvement, leading to complications and sometimes hospitalization.
Trends in the Prevalence of Methylchloroisothiazolinone/Methylisothiazolinone Contact Allergy in North America and Europe
Margo J. Reeder, MD1; Erin Warshaw, MD, MS2,3,4; Srikanth Aravamuthan, MS1; Donald V. Belsito, MD5; Johannes Geier, MD6; Mark Wilkinson, MA, MD7; Amber Reck Atwater, MD8; Ian R. White, FFOM9; Jonathan I. Silverberg, MD, PhD, MPH10,11; James S. Taylor, MD12; Joseph F. Fowler Jr, MD13; Howard I. Maibach, MD14; Joel G. DeKoven, MD, MHSc15; Timo Buhl, MD16; Nina Botto, MD14; Ana Maria Giménez-Arnau, MD, PhD17; Rosella Gallo, MD18; Christen Mowad, MD19; Claudia C. V. Lang, MD20; Vincent A. DeLeo, MD21; Graham Johnston, MB, ChB, CCT22; Melanie D. Pratt, MD23; Knut Brockow, MD24; Brandon L. Adler, MD21; Marie-Claude Houle, MDCM25; Heinrich Dickel, MD26; Marie Louise A. Schuttelaar, MD, PhD27; JiaDe Yu, MD28; Radoslaw Spiewak, MD29; Cory Dunnick, MD30; Francesca Larese Filon, MD31; Skaidra Valiukevi�ienė, MD32; Wolfgang Uter, MD33
doi : 10.1001/jamadermatol.2022.5991
Importance The common use of isothiazolinones as preservatives is a global cause of allergic contact dermatitis. Differences in allowable concentrations of methylisothiazolinone (MI) exist in Europe, Canada, and the US.
Association of Lipid-Lowering Drugs With Risk of PsoriasisA Mendelian Randomization Study
Sizheng Steven Zhao, MD, PhD1; Zenas Z. N. Yiu, MD, PhD2; Anne Barton, MD, PhD3; John Bowes, PhD3
doi : 10.1001/jamadermatol.2022.6051
Importance Lipid pathways have been implicated in the pathogenesis of psoriasis, and some lipid-lowering drugs, such as statins, are hypothesized to have disease-modifying properties. However, large population-level studies are scarce, and causal interpretation of results from traditional observational designs is limited by confounding.
Prevalence and Odds of Depressive and Anxiety Disorders and Symptoms in Children and Adults With Alopecia AreataA Systematic Review and Meta-analysis
Sophie Lauron, MD1; Camille Plasse, MD1; Marion Vaysset, MD1; Bruno Pereira, PhD2; Michel D’Incan, MD, PhD3; Fabien Rondepierre, PhD4; Isabelle Jalenques, MD, PhD5
doi : 10.1001/jamadermatol.2022.6085
Importance Two recent meta-analyses reported a high prevalence of both anxiety and depression in patients with alopecia areata (AA), as well as a positive association of AA with anxiety and depression, without distinguishing between disorders and symptoms.
Risk of Infection in Children With Psoriasis Receiving Treatment With Ustekinumab, Etanercept, or Methotrexate Before and After Labeling Expansion
Maria C. Schneeweiss, MD1,2; Timothy J. Savage, MD, MPH1,3; Richard Wyss, PhD1; Yinzhu Jin, MPH1; Katharina Schoder, MSc1; Joseph F. Merola, MD, MMSc2,4; Robert Sidbury, MD, MPH5; Theresa Oduol, BS1; Sebastian Schneeweiss, MD, ScD1; Robert J. Glynn, PhD, ScD1
doi : 10.1001/jamadermatol.2022.6325
Importance Psoriasis in children is increasingly treated with systemic medications, yet their risk of serious infection is not well characterized in clinical practice. Pediatric clinical trials for these medications were often small and placebo controlled.
Development and Validation of the Morphea Activity Measure in Patients With Pediatric Morphea
Maria Teresa GarcÃa-Romero, MD, MPH1; Megha Tollefson, MD2,3; Elena Pope, MD, MSc4,5; Heather A. Brandling-Bennett, MD6,7; Amy S. Paller, MS, MD8,9,10; Emily Keimig, MD11; Lisa Arkin, MD12; Karolyn A. Wanat, MD13; Stephen R. Humphrey, MD13; Victoria P. Werth, MD14,15; Vikash Oza, MD16; Heidi Jacobe, MD17; Nicole Fett, MD, MSCE18; Kelly M. Cordoro, MD19; Isabel Medina-Vera, PhD20; Yvonne E. Chiu, MD13,21
doi : 10.1001/jamadermatol.2022.6365
Importance Morphea is an insidious inflammatory disorder of the skin and deeper tissues. Determining disease activity is challenging yet important to medical decision-making and patient outcomes.
Clinical Associations of Degos-Like Lesions in Patients With Systemic Sclerosis
Paula Song, MD1; Shufeng Li, MS2,3; Matthew A. Lewis, MD2; David F. Fiorentino, MD, PhD2; Lorinda Chung, MD, MS4,5
doi : 10.1001/jamadermatol.2022.6330
Importance Degos-like lesions are cutaneous manifestations of a small-vessel vasculopathy that appear as atrophic, porcelain-white papules with red, telangiectatic borders. No study has adequately examined Degos-like lesions in patients with systemic sclerosis (SSc).
Values and Preferences of Patients and Caregivers Regarding Treatment of Atopic Dermatitis (Eczema)A Systematic Review
Keon Andre Maleki-Yazdi, MD, MSc1; Anja Fog Heen, MD2; Irene X. Zhao, BHSc1; Gordon H. Guyatt, MD, MSc, OC1,3; Erica A. Suzumura, MSc4; Nima Makhdami, MD1; Lina Chen, BSc5; Tonya Winders, MBA6; Kathryn E. Wheeler, MD7; Julie Wang, MD8; Jonathan Spergel, MD, PhD9; Jonathan I. Silverberg, MD, MPH, PhD10; Peck Y. Ong, MD11; Monica O’Brien, MBS12; Stephen A. Martin, MD, EdM13; Peter A. Lio, MD14; Mary Laura Lind, PhD15; Jennifer LeBovidge, PhD16; Elaine Kim, BScPhrm, RPh17; Joey Huynh, MPT18; Matthew Greenhawt, MD, MBA, MSc19; Winfred T. Frazier, MD, MPH20; Kathy Ellison, MEd21; Korey Capozza, MPH22; Anna De Benedetto, MD23; Mark Boguniewicz, MD19,24; Wendy Smith Begolka, MBS25; Rachel Netahe Asiniwasis, MD, MSc26; Lynda C. Schneider, MD16; Derek K. Chu, MD, PhD1,3,27
doi : 10.1001/jamadermatol.2022.6045
Importance Patient values and preferences can inform atopic dermatitis (AD) care. Systematic summaries of evidence addressing patient values and preferences have not previously been available.
Benign Familial Pemphigus in Skin of Color
Jamie B. Harris, BS1; Tyler Werbel, MD, MS2; Sami K. Saikaly, MD2
Cutaneous Angiosarcoma
Jason C. Klein, MD, PhD1; Arturo R. Dominguez, MD1
Pruritic Rash in a Woman With Endometrial Cancer
Sydney E. Liang, MD1; Randie H. Kim, MD, PhD2
Persistent Green-Blue Plaque in a Healthy Woman
Brenna G. Kelly, BA1; Ting Liu, MD2; Dekker C. Deacon, MD, PhD3,4
Drug Reaction With Eosinophilia and Systemic Symptoms
Matthew S. Krantz, MD1; Elizabeth J. Phillips, MD1
Assessing the Discriminatory Ability of Diagnostic Criteria for Ulcerative Pyoderma Gangrenosum and Its Mimickers
Antonio Ji-Xu, BM BCh1; William Liakos, MD2; Alexander Merleev, PhD1; Marie-Charlotte Brüggen, MD, PhD3,4; Caroline A. Nelson, MD5
Outcomes Associated With Neutropenia and Lymphopenia in Epidermal NecrolysisA Single-Center Retrospective Study of 147 Patients
Saskia Ingen-Housz-Oro, MD1,2,3; Thomas Bettuzzi, MD1,2,3; Bouchra Badaoui, MD4; Nicolas de Prost, MD, PhD2,3,5
Treatment of Trichilemmomas With Topical Sirolimus
Anisha Bhanot, MD1; Katelin Harrell, MD1; Jarad Levin, MD1
Treatment of Recurrent Epidermolysis Bullosa Acquisita With Tofacitinib
Birao Fan, MD1,2,3; Mingyue Wang, MD, PhD1,2,3
